Homology Medicines approves 1-for-18 reverse stock split effective March 25 in connection with Q32 merger

Q32 Bio Inc.

Board approved reverse stock split at 1-for-18 ratio; every 18 shares combine into one.
Reverse split effective at market open on March 25, 2024; Certificate of Amendment filed March 22.
No fractional shares issued; stockholders receive cash in lieu based on March 22 closing price.
Reverse split is a condition to closing of the merger with Q32 Bio Inc.
Post-split common stock trades under new CUSIP 746964105.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.